CompletedNot Applicable

Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.

China841 participantsStarted 2018-03-01

Plain-language summary

Relationships of B-cell Activating Factor Gene Polymorphisms With ulcerative colitis.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosed UC based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results Exclusion Criteria: * rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc

What they're measuring

the genotypes of BAFF

Timeframe: Baseline

Trial details

NCT IDNCT07564895

SponsorSecond Affiliated Hospital of Wenzhou Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-30

View on ClinicalTrials.gov More Ulcerative Colitis (UC) trials